Skip to main content

Table 1 Baseline characteristics of S-TPI cases and those in SITS-UK and VISTA with mRS of ≤ 2 pre treatment

From: Development of a decision analytic model to support decision making and risk communication about thrombolytic treatment

 

S-TPI N = 2,131

 

SITS-UK, N = 2,401

VISTA untreated N = 4,630

Characteristic

 

Cases omitted from analyses (n = 227)

Patients: surviving at 3-months (n = 1,996)

Patients: not surviving to 3-months (n = 405)

 

Age mean (SD)

65.9 (11.4)

67.8 (13.26)

66.7 (12.7)

73.3 (11.3)

70.5 (12.2)

Sex, % male

54.7 %

58.6 %

58.7 %

56.5 %

51.6 %

NIHSS score (median, IQR)

12 (8,17)

12 (7,18)b

12 (8,17)

19 (15,22)

13 (8,18)

Hypertension %

58.8 %

60.36 %

58.0 %

62.5 %

72.1 %a

Diabetes %

20.8 %

14.9 %

12.0 %

17.3 %

21.4 %

Prior stroke %

16.6 %

14.41 %

13.6 %

14.8 %

34.3 %a

Atrial fibrillation %

18.6 %

27.0 %

23.6 %

30.6 %

31.6 %

Onset time to treatment (OTT) minutes (median, IQR)

235 (155,290)

146 (109,175)

150 (120, 175)

150 (120, 178)

-

OTT, % within 3–4.5 h

61.3 %

15.3 %

16.6 %

17.3 %

-

Systolic blood pressure, mm Hg (mean, SD)

152.6 (20.3)

145.5 (21.8)a

146.9 (20.8)

147.9 (21.0)

156.8 (26.7)

Serum glucose mmol/l (median, IQR)

6.78 (5.83,8.58)

6.2 (5.6,7.8)

6.2 (5.4, 7.5)

6.9 (6.0, 8.4)

6.7 (5.8,8.5)

Signs of current infarction on pre-treatment scan %

NA

23.9 %

24.3 %

34.8 %

NA

Congestive heart failure %

12.1 %

4.5 %

4.6 %

6.9 %

NA

  1. aignoring missing values, bNational Institutes of Health Stroke Scale
  2. S-TPI = Stroke-Thrombolytic Predictive Instrument
  3. SITS-UK = Safe Implementation of Treatments in Stroke UK